MX341642B - Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. - Google Patents

Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.

Info

Publication number
MX341642B
MX341642B MX2013013691A MX2013013691A MX341642B MX 341642 B MX341642 B MX 341642B MX 2013013691 A MX2013013691 A MX 2013013691A MX 2013013691 A MX2013013691 A MX 2013013691A MX 341642 B MX341642 B MX 341642B
Authority
MX
Mexico
Prior art keywords
sustained
receptor ligand
active ingredient
composition containing
release composition
Prior art date
Application number
MX2013013691A
Other languages
English (en)
Other versions
MX2013013691A (es
Inventor
Richard Joël
Laredj Faïza
Baronnet Marie-Madeleine
Nourrisson Didier
Harnett Jeremiah
Hacher Béatrice
Mondoly Nathalie
Bertocchi Laurent
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MX2013013691A publication Critical patent/MX2013013691A/es
Publication of MX341642B publication Critical patent/MX341642B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Abstract

La presente invención se refiere a una composición de fármaco de liberación sostenida que consiste esencialmente de microparticulas de un péptido como la sustancia activa y un polímero soluble en agua biocompatible, en particular péptido como ligando receptor de melanocortina. La presente invención se relaciona también a una formulación de inyección que comprende la composición de fármaco de liberación sostenida suspendida en un medio de inyección.
MX2013013691A 2011-06-14 2012-06-13 Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. MX341642B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290270 2011-06-14
PCT/IB2012/001588 WO2012172433A2 (en) 2011-06-14 2012-06-13 A sustained-release composition containing peptides as active ingredient

Publications (2)

Publication Number Publication Date
MX2013013691A MX2013013691A (es) 2014-03-05
MX341642B true MX341642B (es) 2016-08-29

Family

ID=44851715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013691A MX341642B (es) 2011-06-14 2012-06-13 Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.

Country Status (14)

Country Link
US (1) US9415012B2 (es)
EP (1) EP2720684B1 (es)
JP (1) JP6072020B2 (es)
KR (1) KR102038677B1 (es)
CN (1) CN103608003B (es)
AU (1) AU2012270024B2 (es)
BR (1) BR112013027222B1 (es)
CA (1) CA2833676C (es)
ES (1) ES2718655T3 (es)
HK (1) HK1194996A1 (es)
MX (1) MX341642B (es)
RU (1) RU2633483C2 (es)
UA (1) UA114088C2 (es)
WO (1) WO2012172433A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2897559T3 (es) 2011-12-29 2022-03-01 Rhythm Pharmaceuticals Inc Método para tratar trastornos asociados con el receptor de melanocortina-4 en portadores heterocigotos
EP2705835A1 (en) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
BR112015023409B1 (pt) * 2013-03-15 2023-11-28 Rhythm Metabolic, Inc. Complexo iônico, composição farmacêutica compreendendo o referido complexo, seu uso e métodos de produção do referido complexo
RU2725150C2 (ru) 2013-03-15 2020-06-30 Ритм Фармасьютикалз, Инк. Пептидные композиции
WO2018170235A1 (en) 2017-03-15 2018-09-20 Accera, Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
MX2020009900A (es) * 2018-03-23 2021-01-08 Palatin Technologies Inc Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB761061A (en) 1952-06-21 1956-11-07 Leo Ab Method for producing preparations with protracted acth-effect and such preparations
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US7276251B2 (en) * 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
EP1053020B1 (en) * 1998-01-29 2004-03-31 Poly-Med Inc. Absorbable microparticles
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
PL2236151T3 (pl) * 2005-07-08 2012-10-31 Ipsen Pharma Ligandy receptora melanokortyny
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
AR066175A1 (es) 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
KR101662044B1 (ko) * 2007-11-05 2016-10-04 입센 파마 에스.에이.에스. 인슐린 민감성을 치료하기 위한 멜라노코르틴의 용도
CN102083419A (zh) 2008-07-01 2011-06-01 日东电工株式会社 包含表面被覆了的微粒的医药组合物
KR20120099371A (ko) * 2009-08-05 2012-09-10 피어이스 에이지 리포칼린 뮤테인의 조절 방출 제형
CA2769883A1 (en) * 2009-08-05 2011-02-10 Ipsen Pharma S.A.S. Use of melanocortins to treat dyslipidemia
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands

Also Published As

Publication number Publication date
MX2013013691A (es) 2014-03-05
BR112013027222A2 (pt) 2016-12-27
ES2718655T3 (es) 2019-07-03
AU2012270024A1 (en) 2014-01-16
KR20140041531A (ko) 2014-04-04
WO2012172433A3 (en) 2013-01-31
CN103608003B (zh) 2016-05-04
CN103608003A (zh) 2014-02-26
WO2012172433A2 (en) 2012-12-20
US20140127303A1 (en) 2014-05-08
EP2720684A2 (en) 2014-04-23
BR112013027222B1 (pt) 2022-07-12
RU2014100909A (ru) 2015-07-20
CA2833676C (en) 2019-04-23
HK1194996A1 (zh) 2014-10-31
UA114088C2 (xx) 2017-04-25
JP6072020B2 (ja) 2017-02-01
AU2012270024B2 (en) 2016-12-22
US9415012B2 (en) 2016-08-16
EP2720684B1 (en) 2019-01-16
CA2833676A1 (en) 2012-12-20
JP2014517030A (ja) 2014-07-17
KR102038677B1 (ko) 2019-10-30
RU2633483C2 (ru) 2017-10-12

Similar Documents

Publication Publication Date Title
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
MY166518A (en) Nanocapsules containing microemulsions
GB2545368A (en) Diversion-resistant opioid formulations
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
EP2600834A4 (en) COLLAGEN IMPLANTS FOR THE SUSTAINABLE DELIVERY OF MEDICAMENTS
MX341642B (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
MX355833B (es) Metodo y formulacion para inhalacion.
AU2012347200A8 (en) Tablet capable of combatting misuse by injection
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
PH12016500420A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
MY161595A (en) Oral care compositions
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MY163809A (en) Transdermal drug delivery system containing donepezil
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX2013013204A (es) Sistema de suministro de farmaco.
GEP20156332B (en) Pyrazoles as crth2 antagonists
WO2013170086A3 (en) Formulations for the delivery of active ingredients
MY166972A (en) Transdermal delivery system containing galantamine or salts thereof
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
IN2012CH05549A (es)
WO2011133894A3 (en) Protein drug formulations and packages
NZ702849A (en) Genotype- or phenotype-based drug formulation

Legal Events

Date Code Title Description
FG Grant or registration